Aspen Neuroscience Hits Enrollment Milestone in Parkinson’s Cell Therapy Trial

The latest phase of the trial incorporates a new commercial-ready formulation of sasineprocel, featuring a cryopreserved "thaw-and-inject" method. This update aims to simplify clinical delivery by allowing the therapy to be administered immediately upon arrival at medical sites, bypassing complex preparation steps. Damien McDevitt, CEO of Aspen Neuroscience, described the milestone as a vital step toward scaling production and preparing for the pivotal Phase 3 study.

Sasineprocel functions by taking a patient's own skin cells, reprogramming them into induced pluripotent stem cells, and differentiating them into dopaminergic neuron precursors. Because the therapy is autologous—derived from the patient's own biological material—it eliminates the need for immunosuppressive drugs typically required in donor-derived treatments. The FDA has already granted the therapy Fast Track designation, recognizing its potential to address the underlying progression of Parkinson’s disease.